Search Results 51-60 of 8336 for TNF
Cholestatic liver injury. The overall objective of this proposal is to examine the hypothesis that ductular reactive cells induce macrophage TNF-related ...
Treatment with immunosuppressants or anti-cancer drugs; e.g., anti-TNF-α agents, anti-integrin agents, azathioprine or 6-MP, 6-thioguanine, methotrexate ...
... tumor necrosis factor (TNF) therapy. They examined how a patient's genetic risk burden or profile affects the disease course and individual responses to ...
Also known as biologic response modifiers, this newer class of drugs includes tumor necrosis factor (TNF) blockers, such as etanercept (Enbrel, Erelzi ...
A maximum of approximately 50% of subjects with any prior anti-TNF agent use will be allowed in the study. At the end of the double blind period, subjects ...
... tumor necrosis factor (TNF) antagonist (adalimumab subcutaneously [SC]), and an immunomodulator (oral methotrexate) on endoscopic remission in participants ...
The research team has employed aptamer biosensors of this type to detect release of transforming growth factor-beta (TGF-β) and tumor necrosis factor-alpha (TNF ...
Combination Therapy: Anti-TNF Combination Therapy Group (approximately 40-50% of the group): on anti-TNF therapy as described above along with either 15mg ...
The Food and Drug Administration approved the use of anti-tumor necrosis factor and anti-integrin agents for the treatment of ulcerative colitis in 2005 ...
Role of TNF-receptor apoptosis inducing ligand (TRAIL) and hepatocyte apoptosis during co-infection. Significance to patient care. Although there have been ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Thanks to generous benefactors, your gift today can have 5X the impact to advance AI innovation at Mayo Clinic.